197 related articles for article (PubMed ID: 21262027)
21. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
22. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
23. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
24. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
25. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
Kets CM; Niermeijer MF; Massuger LF; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1709-11. PubMed ID: 15468897
[TBL] [Abstract][Full Text] [Related]
26. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
27. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
28. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
30. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
31. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
32. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB; Hollenstein J; Bleiker E; van Beurden M; Valdimarsdottir HB; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2005 Oct; 23(28):6890-8. PubMed ID: 16129845
[TBL] [Abstract][Full Text] [Related]
33. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
34. [Carcinoma of the fallopian tube after prophylactic laparoscopic ovariectomy in a patient with a BRCAI mutation].
Dijkhuizen FP; Huisman A; Boonstra H; Aalders AL
Ned Tijdschr Geneeskd; 2003 May; 147(18):877-9. PubMed ID: 12756880
[TBL] [Abstract][Full Text] [Related]
35. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.
Leblanc E; Narducci F; Farre I; Peyrat JP; Taieb S; Adenis C; Vennin P
Gynecol Oncol; 2011 Jun; 121(3):472-6. PubMed ID: 21411127
[TBL] [Abstract][Full Text] [Related]
36. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
Chand M; Moore PJ; Clarke AD; Nash GF; Hickisk T
World J Surg Oncol; 2007 Sep; 5():102. PubMed ID: 17850658
[TBL] [Abstract][Full Text] [Related]
37. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
38. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
[TBL] [Abstract][Full Text] [Related]
39. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
[TBL] [Abstract][Full Text] [Related]
40. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
Escobar PF; Starks DC; Fader AN; Barber M; Rojas-Espalliat L
Gynecol Oncol; 2010 Oct; 119(1):43-7. PubMed ID: 20579712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
